Clinical

Dataset Information

0

ISIS 2503 in Treating Patients With Metastatic and/or Locally Recurrent Colorectal Cancer


ABSTRACT: RATIONALE: ISIS 2503 may kill cancer cells by inhibiting a gene that promotes the development and growth of cancer. PURPOSE: Phase II trial to study the effectiveness of ISIS 2503 in treating patients who have metastatic and/or locally recurrent colorectal cancer.

DISEASE(S): Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2003607 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| EGAS00001006871 | EGA
2022-03-11 | PXD026630 | Pride
2014-05-01 | E-GEOD-56303 | biostudies-arrayexpress
| 116635 | ecrin-mdr-crc
2014-05-01 | GSE56303 | GEO
| 2006859 | ecrin-mdr-crc
2017-07-27 | GSE101920 | GEO
| PRJNA1098085 | ENA
2010-08-05 | E-TABM-913 | biostudies-arrayexpress
2019-05-02 | GSE100243 | GEO